Toolkit Survey
- 239 respondents answered the Toolkit
- 70% of respondents use the quarterly reports frequently, 25.3% use them occasionally and 4.7% never use these reports.
- All reporting periods shown in Toolkit reports quarterly, quarter on quarter and financial year are used frequently or occasionally by 90.2% of users.
- 73.6% of respondents who answeredthe question about how often they used PCT cluster information within Prescribing Toolkit use this facility.
- 71.8% of respondents requested a facility to select their own cluster.
- Most respondents (69.5%) would not use a different cluster for each Toolkit comparator.
- Only 20.9% of the 155 respondents always use the exclude practice function in Toolkit. The main use of this function is to exclude outliers and pseudo practices such as OOH services and walk-in centres
- The anonymise data facility currently provided in Toolkit is not widely used with only 8% of respondents indicating that they use this facility.
- 62.7% of respondents use the numerator and denominator values shown in Toolkit reports
- The most frequently used Toolkit report (outside of QIPP) is the Potential generic savings report which 61.4% of respondents use frequently.
- Other frequently used reports include Low cost statins as a % of statins (new) - 51.2%, Antibacterial drugs items/STAR PU - 49.2%, Pravastatin / Simvastatin as a % statins - 40.8%, Benzodiazepine receptors ADQ/STAR PU - 40.6% and Antibacterial drugs ADQ/STAR PU - 39.7%.
- Toolkit reports which are not used on a regular basis by information system users include:
Calcium-channel blocker ADQ/STAR PU (10.2%), Anti-epileptics ADQ/STAR PU
(10.3%)Ulcer Healing drugs NIC/ ADQ (12.9%)
Frequent Usage of Toolkit Reports
Report / % of users who use reports frequently / Report / % of users who use reports frequently
Potential Generic Savings Report / 61.4 / Analgesics ADQ/ STAR PU / 20.5
Low cost statins as a % of statins (new) / 51.2 / Bisphosphonates ADQ/STAR PU / 20.5
Antibacterial drugs items/STAR PU / 49.2 / Bronchodilators ADQ/STAR PU / 19.7
Pravastatin / Simvastatin as a % statins / 40.8 / Cox-2 inhibitors ADQ/STAR PU / 18.8
Benzodiazepine receptors (HC) ADQ/STAR PU / 40.6 / Entral feeds (other) NIC/PU / 18.7
Antibacterial drugs ADQ/STAR PU / 39.7 / Specialist Drug Report / 18.5
Percentage generic items / 38.9 / Entral feeds (tube) NIC/PU / 17.4
Entral feeds (sip) NIC/PU / 37.9 / Antidepressant ADQ/STAR PU / 17.3
All Prescribing NIC/ASTRO PU / 34.1 / Entral feeds (paed) NIC/PU / 17.1
Benzodiazepines (Caps/Tabs) ADQ/STAR PU / 33.1 / Dementia ADQ/STAR PU / 14.4
Lipid-regulating drugs ADQ/STAR PU / 32.0 / Antiplatelets ADQ/STAR PU / 14.2
Drugs affecting renin-angotensin system ADQ/STAR PU / 26.4 / Percentage cost new drugs / 13.6
Inhaled Corticosteroids ADQ/STAR PU / 26.4 / Ulcer Healing drugs ADQ/ STAR PU / 13.5
Inhaled Corticosteroids NIC/ ADQ / 26.0 / Ulcer Healing drugs NIC/ ADQ / 12.9
Oral NSAIDs NIC/ADQ / 25.8 / Anti-epileptics ADQ/STAR PU / 10.3
Proton Pump inhibitors ADQ/STAR PU / 25.6 / Calcium-Channel blockers ADQ/STAR PU / 10.2
Statins ADQ/STAR PU / 22.0 / Obesity ADQ/STAR PU / 8.1
Oral Antidiabetics ADQ/STAR PU / 21.8 / Treatment of parkinsonism ADQ/STAR PU / 6.3